SkinBioTherapeutics PLC Business Update (9427X)
16 August 2018 - 4:00PM
UK Regulatory
TIDMSBTX
RNS Number : 9427X
SkinBioTherapeutics PLC
16 August 2018
SkinBioTherapeutics plc
Business update
Manchester, UK - 16 August 2018 - SkinBioTherapeutics plc (AIM:
SBTX, the "Company"), a life science company focused on skin
health, is pleased to provide the following update:
Manufacturing
The Company, with its third party manufacturer, has now achieved
significant manufacturing scale up, with no detrimental impact upon
the active properties of the SkinBiotix(R) technology.
In addition the material, which to date has been manufactured
and supplied in a liquid form, has now been successfully freeze
dried. The ability to freeze dry the material is an important steps
towards commercialisation as it enables mass production, storage
and transportation.
The SkinBiotix(R) technology has been shown to be stable and
effective within the cream formulation for 24 hours. The human
study, which is due to commence in September, is subject to the
Company's ongoing work to confirm stability of the current
formulation over an extended timeframe. The Company expects to
provide an update on this in the coming weeks.
Financial Position
The Company ended the 12 months to 30 June 2018 with a cash
balance of GBP3.2m (31 December 2017: GBP3.6m).
The Company will publish its full year results in October.
Dr Cath O'Neill, CEO of SkinBioTherapeutics, commented:
"The progress we've made so far in manufacturing and
freeze-drying the lysate is very encouraging. The current
formulation is undergoing extended stability studies in preparation
for the human study."
The information communicated within this announcement is deemed
to constitute inside information as stipulated under the Market
Abuse Regulations (EU) No. 596/2014 and has been arranged for
release by Doug Quinn, CFO of the Company. Upon the publication of
this announcement, this inside information is now considered to be
in the public domain.
For more information, please contact:
SkinBioTherapeutics plc Tel: +44 (0) 161 468
Dr. Cath O'Neill, CEO 2760
Doug Quinn, CFO
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213
Adviser) 0880
Tony Rawlinson / Sandy Jamieson / Richard
Nash
Turner Pope Investments (Joint Broker) Tel: +44 (0) 20 3621
Ben Turner / James Pope 4120
Northland Capital Partners (Joint Broker)
Tom Price Tel: +44 (0) 20 3861
6625
Instinctif Partners (Media Relations) Tel: +44 (0) 20 7457
Melanie Toyne-Sewell / Deborah Bell 2020
SkinBio@instinctif.com
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R), is based upon discoveries made by CEO Dr. Catherine
O'Neill and Professor Andrew McBain.
SkinBioTherapeutics' platform applies research discoveries made
on the activities of lysates derived from probiotic bacteria when
applied to the skin. The Company has shown that the SkinBiotix(R)
platform can improve the barrier effect of skin models, protect
skin models from infection and repair skin models. Proof of
principle studies have shown that the SkinBiotix(R) platform has
beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer
office of the University of Manchester for the discovery of
SkinBiotix(R). The platform was subsequently spun out of the
University of Manchester in March 2016 and was funded by OptiBiotix
(AIM: OPTI).
The Company joined AIM in April 2017 concurrent with raising
GBP4.5 million from a placing of new ordinary shares.
The Company is based in Manchester, UK. For more information,
visit www.skinbiotherapeutics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDQELFFVVFFBBL
(END) Dow Jones Newswires
August 16, 2018 02:00 ET (06:00 GMT)
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2024 to May 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From May 2023 to May 2024